A University of Minnesota research team earned a $11.6 million grant to work with the Mayo Clinic on a device designed to ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX stock update.

Amsino has taken a significant step forward in our mission to advance healthcare worldwide. We are proud to announce the establishment of Amsino Scientific Inc., a new medical device manufacturing, ...

The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

At the recent ATTD 2025 meeting, participants discussed recent progress and remaining challenges in developing a fully closed ...

The firm’s platform of analytical tools are used in the development of a new class of drugs known as RNA therapeutics – a ...

Medera announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy ...

The biotech is based in Radnor, Pennsylvania and is also one of the 10 Pump and Dump Stocks Favored by Hedge Funds. Mineralys Therapeutics ... while the Advance-HTN trial, conducted with the ...

Biosensors are changing how we monitor health, but rapid innovation raises tough questions around privacy, regulation, and ...

Three-dimensional models allow researchers to better represent complex tissues and cell-cell interactions. This article ...